Skip Navigation


JAC Advance Access originally published online on March 13, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/4/757    most recent
dkg172v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Stiegler, G.
Right arrow Articles by Katinger, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stiegler, G.
Right arrow Articles by Katinger, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 757-759
© 2003 The British Society for Antimicrobial Chemotherapy

Leading Article

Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection

Gabriela Stiegler* and Hermann Katinger

Institute of Applied Microbiology, Vienna, Austria

Keywords: HIV, neutralizing antibodies

The first 10% of the full text of this article appears below.

In 1981 unusual cases of severe immune deficiency were reported. Two years later the cause of the acquired immunodeficiency syndrome (AIDS) was identified: a retrovirus, designated the human immunodeficiency virus (HIV), that caused a loss of important immune functions leading to a dramatic vulnerability to a variety of bacterial, viral and fungal infections. The finding that the presence of neutralizing antibodies correlated with the disease status suggested that infusion with hyperimmune plasma and human HIV-specific immunoglobulin (HIVIG) obtained from chronically HIV-1-infected asymptomatic donors may be of benefit to patients. However, early clinical studies were disappointing. No clear benefits were found for the majority of patients treated.1

The introduction of highly active antiretroviral therapy (HAART) in 1996 caused great excitement. HAART drugs inhibit viral replication within infected cells by interfering . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
J. G. Joyce, I. J. Krauss, H. C. Song, D. W. Opalka, K. M. Grimm, D. D. Nahas, M. T. Esser, R. Hrin, M. Feng, V. Y. Dudkin, et al.
An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions
PNAS, October 14, 2008; 105(41): 15684 - 15689.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
N. Huarte, M. Lorizate, R. Maeso, R. Kunert, R. Arranz, J. M. Valpuesta, and J. L. Nieva
The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 4E10 Monoclonal Antibody Is Better Adapted to Membrane-Bound Epitope Recognition and Blocking than 2F5
J. Virol., September 15, 2008; 82(18): 8986 - 8996.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. R. Miranda, M. Duval, H. Doherty, M. S. Seaman, M. R. Posner, and L. A. Cavacini
The Neutralization Properties of a HIV-Specific Antibody Are Markedly Altered by Glycosylation Events Outside the Antigen-Binding Domain
J. Immunol., June 1, 2007; 178(11): 7132 - 7138.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
B. F. Haynes, J. Fleming, E. W. St. Clair, H. Katinger, G. Stiegler, R. Kunert, J. Robinson, R. M. Scearce, K. Plonk, H. F. Staats, et al.
Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies
Science, June 24, 2005; 308(5730): 1906 - 1908.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
C. Armbruster, G. M. Stiegler, B. A. Vcelar, W. Jager, U. Koller, R. Jilch, C. G. Ammann, M. Pruenster, H. Stoiber, and H. W. D. Katinger
Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12
J. Antimicrob. Chemother., November 1, 2004; 54(5): 915 - 920.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M.-Y. Zhang, X. Xiao, I. A. Sidorov, V. Choudhry, F. Cham, P. F. Zhang, P. Bouma, M. Zwick, A. Choudhary, D. C. Montefiori, et al.
Identification and Characterization of a New Cross-Reactive Human Immunodeficiency Virus Type 1-Neutralizing Human Monoclonal Antibody
J. Virol., September 1, 2004; 78(17): 9233 - 9242.
[Abstract] [Full Text] [PDF]